Eli Lilly & Co (0Q1G) Share Forecast & Price Target

32 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0Q1G Analyst Ratings

Strong Buy

22 Buy

1 Hold

1 Sell

Based on 24 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0Q1G Stock 12 Month Forecast

Average Price Target

CHF1,225.66

▲(20.16% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is CHF1,225.66 with a high forecast of CHF1,354.20 and a low forecast of CHF771.48. The average price target represents a 20.16% change from the last price of CHF1,020.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"454":"CHF454","1355":"CHF1,355","679.25":"CHF679.3","904.5":"CHF904.5","1129.75":"CHF1,129.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1354.1961675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF1.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1225.6635035913043,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF1.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":771.481453,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF771.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[454,679.25,904.5,1129.75,1355],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,975,1004.1689359615384,1033.3378719230768,1062.5068078846155,1091.6757438461539,1120.8446798076923,1150.0136157692307,1179.1825517307693,1208.3514876923077,1237.5204236538461,1266.6893596153845,1295.858295576923,1325.0272315384616,{"y":1354.1961675,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,975,994.2818079685619,1013.5636159371237,1032.8454239056857,1052.1272318742474,1071.4090398428093,1090.6908478113712,1109.9726557799331,1129.254463748495,1148.536271717057,1167.8180796856186,1187.0998876541805,1206.3816956227424,{"y":1225.6635035913043,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,975,959.3447271538462,943.6894543076924,928.0341814615384,912.3789086153846,896.7236357692308,881.068362923077,865.413090076923,849.7578172307692,834.1025443846154,818.4472715384616,802.7919986923077,787.1367258461538,{"y":771.481453,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":455.661,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.661,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456.842,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.165,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":712.148,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":677.287,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":680,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1020,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":975,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF1,354

Average Price TargetCHF1,226

Lowest Price TargetCHF771.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

CHF1,129.32→CHF1,323.01

Buy

29.71%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,612 from $1,376 at TruistEli Lilly price target raised to $1,612 from $1,376 at Truist

Geoff Meacham

Citi

CHF1,313.16→CHF1,354.2

Buy

32.76%

Upside

Reiterated

10/30/26

Analysts Conflicted on These Healthcare Names: Alcon (NYSE: ALC), Eli Lilly & Co (NYSE: LLY) and Moderna (NASDAQ: MRNA)

Evan Seigerman

BMO Capital

CHF1,149.01→CHF1,354.2

Buy

32.76%

Upside

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tenet Healthcare (NYSE: THC), Eli Lilly & Co (NYSE: LLY) and DaVita (NYSE: DVA)

Asad Haider

Goldman Sachs

CHF1,159.68→CHF1,291

Buy

26.57%

Upside

Assigned

10/30/26

Eli Lilly price target raised to $1,573 from $1,413 at Goldman SachsEli Lilly price target raised to $1,573 from $1,413 at Goldman Sachs

Terence Flynn

Morgan Stanley

CHF1,173.64→CHF1,309.88

Buy

28.42%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,596 from $1,430 at Morgan StanleyEli Lilly price target raised to $1,596 from $1,430 at Morgan Stanley

Louise Chen

Scotiabank

CHF1,066.94→CHF1,317.26

Buy

29.14%

Upside

Reiterated

10/30/26

Eli Lilly & Co (LLY) Gets a Buy from Scotiabank

Chris Schott

J.P. Morgan

CHF1,231.09→CHF1,354.2

Buy

32.76%

Upside

Assigned

10/30/26

Eli Lilly price target raised to $1,650 from $1,500 at JPMorganEli Lilly price target raised to $1,650 from $1,500 at JPMorgan

Jasper Hellweg

Argus Research

CHF1,066.94→CHF1,272.12

Buy

24.72%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,550 from $1,300 at ArgusEli Lilly price target raised to $1,550 from $1,300 at Argus

Michael Yee

UBS

CHF1,169.53→CHF1,333.68

Buy

30.75%

Upside

Assigned

10/30/26

Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Kymera Therapeutics (KYMR)

Ilya Zubkov

Freedom Capital Markets

CHF1,149.01→CHF1,313.16

Buy

28.74%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,600 from $1,400 at Freedom BrokerEli Lilly price target raised to $1,600 from $1,400 at Freedom Broker

Trung Huynh

RBC Capital

CHF1,231.09→CHF1,313.16

Buy

28.74%

Upside

Assigned

10/29/26

RBC Capital Remains a Buy on Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

CHF1,146.55→CHF1,228.63

Buy

20.45%

Upside

Reiterated

10/29/26

Eli Lilly’s Strong Execution, Obesity Franchise Upside Drive Raised $1,497 Price Target and Reaffirmed Buy Rating

Akash Tewari

Jefferies

CHF1,181.84→CHF1,321.37

Buy

29.55%

Upside

Assigned

10/29/26

Eli Lilly price target raised to $1,610 from $1,440 at JefferiesEli Lilly price target raised to $1,610 from $1,440 at Jefferies

Mohit Bansal

Wells Fargo

CHF1,091.56→CHF1,231.09

Buy

20.69%

Upside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Alnylam Pharma (NASDAQ: ALNY) and Tenet Healthcare (NYSE: THC)

Emily Field

Barclays

CHF1,149.01

Buy

12.65%

Upside

Reiterated

10/29/26

Eli Lilly & Co (LLY) Gets a Buy from Barclays

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

CHF1,129.32→CHF1,323.01

Buy

29.71%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,612 from $1,376 at TruistEli Lilly price target raised to $1,612 from $1,376 at Truist

Geoff Meacham

Citi

CHF1,313.16→CHF1,354.2

Buy

32.76%

Upside

Reiterated

10/30/26

Analysts Conflicted on These Healthcare Names: Alcon (NYSE: ALC), Eli Lilly & Co (NYSE: LLY) and Moderna (NASDAQ: MRNA)

Evan Seigerman

BMO Capital

CHF1,149.01→CHF1,354.2

Buy

32.76%

Upside

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Tenet Healthcare (NYSE: THC), Eli Lilly & Co (NYSE: LLY) and DaVita (NYSE: DVA)

Asad Haider

Goldman Sachs

CHF1,159.68→CHF1,291

Buy

26.57%

Upside

Assigned

10/30/26

Eli Lilly price target raised to $1,573 from $1,413 at Goldman SachsEli Lilly price target raised to $1,573 from $1,413 at Goldman Sachs

Terence Flynn

Morgan Stanley

CHF1,173.64→CHF1,309.88

Buy

28.42%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,596 from $1,430 at Morgan StanleyEli Lilly price target raised to $1,596 from $1,430 at Morgan Stanley

Louise Chen

Scotiabank

CHF1,066.94→CHF1,317.26

Buy

29.14%

Upside

Reiterated

10/30/26

Eli Lilly & Co (LLY) Gets a Buy from Scotiabank

Chris Schott

J.P. Morgan

CHF1,231.09→CHF1,354.2

Buy

32.76%

Upside

Assigned

10/30/26

Eli Lilly price target raised to $1,650 from $1,500 at JPMorganEli Lilly price target raised to $1,650 from $1,500 at JPMorgan

Jasper Hellweg

Argus Research

CHF1,066.94→CHF1,272.12

Buy

24.72%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,550 from $1,300 at ArgusEli Lilly price target raised to $1,550 from $1,300 at Argus

Michael Yee

UBS

CHF1,169.53→CHF1,333.68

Buy

30.75%

Upside

Assigned

10/30/26

Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Kymera Therapeutics (KYMR)

Ilya Zubkov

Freedom Capital Markets

CHF1,149.01→CHF1,313.16

Buy

28.74%

Upside

Reiterated

10/30/26

Eli Lilly price target raised to $1,600 from $1,400 at Freedom BrokerEli Lilly price target raised to $1,600 from $1,400 at Freedom Broker

Trung Huynh

RBC Capital

CHF1,231.09→CHF1,313.16

Buy

28.74%

Upside

Assigned

10/29/26

RBC Capital Remains a Buy on Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

CHF1,146.55→CHF1,228.63

Buy

20.45%

Upside

Reiterated

10/29/26

Eli Lilly’s Strong Execution, Obesity Franchise Upside Drive Raised $1,497 Price Target and Reaffirmed Buy Rating

Akash Tewari

Jefferies

CHF1,181.84→CHF1,321.37

Buy

29.55%

Upside

Assigned

10/29/26

Eli Lilly price target raised to $1,610 from $1,440 at JefferiesEli Lilly price target raised to $1,610 from $1,440 at Jefferies

Mohit Bansal

Wells Fargo

CHF1,091.56→CHF1,231.09

Buy

20.69%

Upside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Alnylam Pharma (NASDAQ: ALNY) and Tenet Healthcare (NYSE: THC)

Emily Field

Barclays

CHF1,149.01

Buy

12.65%

Upside

Reiterated

10/29/26

Eli Lilly & Co (LLY) Gets a Buy from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

REPLReplimune Group

VSTMVerastem

OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Louise ChenScotiabank

Success Rate

30/37 ratings generated profit

Average Return

+10.24%

Copying Louise Chen's trades and holding each position for 3 Months would result in 81.08% of your transactions generating a profit, with an average return of +10.24% per trade.

1 Year

Geoff MeachamCiti

Success Rate

43/44 ratings generated profit

Average Return

+45.75%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +45.75% per trade.

2 Years

Terence FlynnMorgan Stanley

Success Rate

49/49 ratings generated profit

Average Return

+80.10%

Copying Terence Flynn's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +80.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q1G Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0Q1G has received 80 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. 0Q1G average Analyst price target in the past 3 months is 1,225.66.

Each month's total comprises the sum of three months' worth of ratings.

0Q1G Financial Forecast

0Q1G Earnings Forecast

Next quarter’s earnings estimate for 0Q1G is CHF9.12 with a range of CHF8.36 to CHF10.23. The previous quarter’s EPS was CHF6.16. 0Q1G beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Sales Forecast

Next quarter’s sales forecast for 0Q1G is CHF20.11B with a range of CHF19.26B to CHF20.66B. The previous quarter’s sales results were CHF20.10B. 0Q1G beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Stock Forecast FAQ

What is GB:0Q1G’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,225.66.

What is GB:0Q1G’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 20.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly & Co a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 22 buy ratings, 1 hold ratings and 1 sell ratings.

What is Eli Lilly & Co’s share price target?

The average share price target for Eli Lilly & Co is 1,225.66. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF1,354.20 ,and the lowest forecast is CHF771.48. The average share price target represents 20.16% Increase from the current price of CHF1,020.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of Eli Lilly & Co?

To buy shares of GB:0Q1G, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (0Q1G) Share Forecast & Price Target

0Q1G Analyst Ratings

0Q1G Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

0Q1G Analyst Recommendation Trends

0Q1G Financial Forecast

0Q1G Earnings Forecast

0Q1G Sales Forecast

0Q1G Stock Forecast FAQ

Detailed List of Analyst Forecasts